Structure of a substrate complex of mammalian cytochrome P4502C5 at 2.3 Å resolution:: Evidence for multiple substrate binding modes

被引:174
作者
Wester, MR
Johnson, EF
Marques-Soares, C
Dansette, PM
Mansuy, D
Stout, CD
机构
[1] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA
[2] Univ Paris 05, UMR 8601 CNRS, Chim & Biochim Pharmacol & Toxicol Lab, F-75270 Paris 06, France
[3] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA
关键词
D O I
10.1021/bi0273922
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The structure of rabbit microsomal cytochrome P450 2C5/3LVdH complexed with a substrate, 4-methyl-N-methyl-N-(2-phenyl-2H-pyrazol-3-yl)benzenesulfonamide (DMZ), was determined by X-ray crystallography to 2.3 Angstrom resolution. Substrate docking studies and electron density maps indicate that DMZ binds to the enzyme in two antiparallel orientations of the long axis of the substrate. One orientation places the principal site of hydroxylation, the 4-methyl group, 4.4 A from the heme Fe, whereas the alternate conformation positions the second, infrequent site of hydroxylation at >5.9 A from the heme Fe. Comparison of this structure to that obtained previously for the enzyme indicates that the protein closes around the substrate and prevents open access of water from bulk solvent to the heme Fe. This reflects a similar to1.5 Angstrom movement of the F and G helices relative to helix I. The present structure provides a complete model for the protein from residues 27-488 and defines two new helices F' and G'. The G, helix is likely to contribute to interactions of the enzyme with membranes. The relatively large active site, as compared to the volume occupied by the substrate, and the flexibility of the enzyme are likely to underlie the capacity of drug-metabolizing enzymes to metabolize structurally diverse substrates of different sizes.
引用
收藏
页码:6370 / 6379
页数:10
相关论文
共 31 条
[1]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[2]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[3]   Engineering microsomal cytochrome P4502C5 to be a soluble, monomeric enzyme - Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding [J].
Cosme, J ;
Johnson, EF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (04) :2545-2553
[4]   STRUCTURE OF CYTOCHROME P450ERYF INVOLVED IN ERYTHROMYCIN BIOSYNTHESIS [J].
CUPPVICKERY, JR ;
POULOS, TL .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (02) :144-153
[5]  
GOTOH O, 1992, J BIOL CHEM, V267, P83
[6]   OXIDATION REDUCTION PROPERTIES OF RAT-LIVER CYTOCHROMES-P-450 AND NADPH CYTOCHROME-P-450 REDUCTASE RELATED TO CATALYSIS IN RECONSTITUTED SYSTEMS [J].
GUENGERICH, FP .
BIOCHEMISTRY, 1983, 22 (12) :2811-2820
[7]   Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily [J].
Ha-Duong, NT ;
Dijols, S ;
Marques-Soares, C ;
Minoletti, C ;
Dansette, PM ;
Mansuy, D .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (22) :3622-3631
[8]   Interaction of new sulfaphenazole derivatives with human liver cytochrome P4502Cs: Structural determinants required for selective recognition by CYP2C9 and for inhibition of human CYP2Cs [J].
Ha-Duong, NT ;
Marques-Soares, C ;
Dijols, S ;
Sari, MA ;
Dansette, PM ;
Mansuy, D .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 394 (02) :189-200
[9]   Pivotal role of water in the mechanism of P450BM-3 [J].
Haines, DC ;
Tomchick, DR ;
Machius, M ;
Peterson, JA .
BIOCHEMISTRY, 2001, 40 (45) :13456-13465
[10]  
HSU MH, 1993, J BIOL CHEM, V268, P6939